Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT2527 in Advanced Solid Tumors
NCT05159518Phase 1Completed
- Sponsor
- Prelude Therapeutics
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PRT2527 in sarcoma, castration-resistant prostate cancer (CRPC), breast cancer and 2 more, sponsored by Prelude Therapeutics. Primary endpoints: Dose limiting toxicities at Day 21, Maximally tolerated dose at 1 year and 1 more. Started Feb 2022; status: completed.
02
Drugs
PRT2527
03
Conditions
sarcomacastration-resistant prostate cancer (CRPC)breast cancernon-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05159518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159518.